Cambium Medical Technologies LLC is categorized under Biological Research in Atlanta, GA and active since 2013.
Cambium Medical Technologies LLC was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Biological Research business, which does work in the B2B market, and is classified as a Biological Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Terry Walts at the company’s single location by writing to 2986 Greenwillow Drive Ne, Atlanta, Georgia GA 30345 or by phoning (404) 831-4496. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Cambium Medical Technologies LLC |
| Contact Person: | Terry Walts |
| Address: | 2986 Greenwillow Drive Ne, Atlanta, Georgia 30345 |
| Phone Number: | (404) 831-4496 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biological Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Cambium Medical Technologies LLC was started in 2013 to provide professional Biological Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Terry Walts for inquiries that concern Cambium Medical Technologies LLC by calling the company number (404) 831-4496, as your correspondence is most welcome. Additionally, the physical location of the single location of Cambium Medical Technologies LLC can be found at the coordinates 33.845866,-84.265925 as well as the street address 2986 Greenwillow Drive Ne in Atlanta, Georgia 30345.
For its online presence, you may visit Cambium Medical Technologies LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.